![]() |
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
Sponsored by: |
Ono Pharma |
---|---|
Information provided by: | Ono Pharma |
ClinicalTrials.gov Identifier: | NCT00212693 |
The purpose of this study is to evaluate the efficacy and safety of ONO-2506PO in patients with Parkinson's Disease
Condition | Intervention | Phase |
---|---|---|
Parkinson's Disease |
Drug: ONO-2506PO |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double-Blind, Dose Comparison, Parallel Assignment, Safety/Efficacy Study |
Official Title: | Controlled Study of ONO-2506PO in Patients With Parkinson's Disease in Japan |
Ages Eligible for Study: | 20 Years to 79 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Study ID Numbers: | ONO-2506PO-03 |
Study First Received: | September 13, 2005 |
Last Updated: | April 3, 2006 |
ClinicalTrials.gov Identifier: | NCT00212693 History of Changes |
Health Authority: | Japan: Ministry of Health, Labor and Welfare |
ONO-2506PO, Parkinson's disease |
Ganglion Cysts Movement Disorders Parkinson Disease Basal Ganglia Diseases |
Central Nervous System Diseases Parkinsonian Disorders Neurodegenerative Diseases Brain Diseases |
Movement Disorders Parkinson Disease Nervous System Diseases Basal Ganglia Diseases |
Central Nervous System Diseases Parkinsonian Disorders Neurodegenerative Diseases Brain Diseases |